Hear insights from Renslow Sherer, MD, on some of the most important data reported at the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020 Virtual), including new findings on long-term 2-drug and 3-drug antiretroviral therapy, the efficacy of newer 3-drug regimens in patients with baseline NRTI resistance, the latest information on investigational HIV treatment approaches, and updates on important comoribidities in patients with HIV, including COVID-19.
In this episode, Dr. Sherer discusses results from key studies reported at the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020 Virtual), including studies on long-term 2-drug and 3-drug antiretroviral therapy, newer 3-drug regimens in patients with baseline NRTI resistance, investigational HIV treatment approaches, and important comoribidities in patients with HIV, including COVID-19.
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
University of Chicago
Chicago, Illinois
Content based on a CME program supported by independent educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.
Link to full program:
https://bit.ly/35nGqph